Sirtuin Family: NAD+-Dependent Deacylases and Substrate Diversity
Sirtuins (class III HDACs; NAD+-dependent deacylases; 7 mammalian paralogs SIRT1–7; use NAD+ + acetyl-Lys → deacetylated-Lys + O-acetyl-ADP-ribose + nicotinamide; nicotinamide is product inhibitor (Ki ~100 μM); 2′-O-acetyl-ADP-ribose second messenger?); SIRT1 (nuclear/cytoplasmic; ~750 aa; catalytic domain 270–498 aa; substrates: H3K9ac/H4K16ac (chromatin); p53 Lys382 (apoptosis ↓); NF-κB RelA Lys310 (inflammatory transcription ↓); PGC-1α Lys183/450 (mitochondrial biogenesis ↑); FOXO3a Lys242/245/259 (nuclear export → stress resistance); LKB1 (SIRT1 deacetylates LKB1 → AMPK activation; circular AMPK-SIRT1 feedforward); HIF-1α Lys532 (VHL-independent destabilisation → SIRT1 ↓ HIF-1α activity); DNMT3L (methylation)); SIRT2 (cytoplasm; α-tubulin Lys40 (microtubule deacetylation; cell cycle; HDAC6 also); H4K16ac; FOXO3a; PEPCK1 gluconeogenesis; CDH1 cell cycle; inhibitors: AGK2/AK-7 neuroprotection in PD); SIRT3 (mitochondrial matrix; acetylproteome: SOD2 Lys68 (+50% activity; ↓ROS); IDH2 Lys413 (↓ NADPH; Nrf2-GSH); LCAD Lys42 (↑ FA β-oxidation); PDHA1 Lys321 (↑ acetyl-CoA); CypD Lys166 (mPTP ↓); complex I NDUFA9; ATP synthase α subunit; SDH; SIRT3 KO: hyperacetylated mitochondria → mtROS ↑ → cancer/metabolic disease); SIRT4 (mitochondrial inner membrane; lipoamidase/delipoylase (not deacetylase; removes lipoyl from E2 subunit DLAT of PDH → PDH activity ↓); GDH deacetylation? → insulin secretion; SIRT4 is atypical; substrate: DLAT Lys lipoyl); SIRT5 (mitochondria; desuccinylase/demalonylase/deglutarylase; succinyl-Lys (not acetyl) removal; CPS1 Lys1291 (succinylation; SIRT5 → CPS1 active → urea cycle); SDHA Lys335 desuccinylation; GLS2 desuccinylation; wide succinylomic survey: >2500 succinylation sites SIRT5-regulated); SIRT6 (nuclear; H3K9ac (pericentric heterochromatin; telomere; DNA damage repair (SIRT6 deacetylates H3K9ac at DSB → NHEJ/HR ↑)); H3K56ac; CtIP (DSB resection); SIRT6 Lys33 autoacetylation; TNFα/HIF-1α H3K9ac at target promoters (SIRT6 ↓ → NF-κB ↑; SIRT6 ↑ → NF-κB ↓)); SIRT7 (nucleolar; H3K18ac at ribosomal protein genes; RNA pol I; cancer; SIRT7 KO → dilated cardiomyopathy); NAD+ biosynthesis: Preiss-Handler (nicotinic acid → NAPRT → NAMN → NMNAT → NaAD → NADS → NAD+); Kynurenine/de novo (Trp → kynurenine → quinolinate → QPRT → NAMN); Salvage (nicotinamide → NAMPT (rate-limiting; Visfatin; dimer; Phe193/Phe423 pocket; CHS-828/STF31 inhibitors) → NMN → NMNAT1/2/3 → NAD+); NR (nicotinamide riboside → NRK1/2 → NMN → NMNAT).
Spirulina Mechanisms in Sirtuin/NAD+ Biology
AMPK-NAMPT NAD+ Salvage Upregulation
AMPK-NAMPT axis (NAMPT (rate-limiting NAD+ salvage enzyme; ~55 kDa; Phe193 substrate Phe binding; NAMPT → NMN → NMNAT → NAD+; NAMPT regulation: AMPK → SIRT1 → H3K9ac at NAMPT promoter ↓ (SIRT1 deacetylates H3K9ac at NAMPT promoter → NAMPT gene open); NF-κB drives NAMPT transcription (eNAMPT secretion → iNAMPT raises NAD+); SIRT1 creates feedforward: SIRT1 → NAMPT ↑ → NAD+ ↑ → SIRT1 ↑; mTOR ↓ (AMPK) → NAMPT ↑ (mTOR represses NAMPT? → evidence limited but AMPK-mTOR-NAMPT proposed); circadian NAMPT (CLOCK/BMAL1 NAMPT oscillation → NAD+ circadian; AMPK → CRY1/2 degradation → CLOCK/BMAL1 active → NAMPT)): spirulina AMPK +30–60% → (1) NAMPT expression +15–25%; (2) NF-κB ↓ (spirulina) partially counters NF-κB-driven NAMPT (net: NAMPT not reduced by NF-κB ↓ because AMPK dominant); (3) NMN (NMN: intermediate; spirulina niacinamide/B3 ~3–15 mg/100g → nicotinamide → NAMPT → NMN); NAD+ tissue levels +15–25% (spirulina 8–12 weeks; HPLC; liver/skeletal muscle models); SIRT1 activity +20–35% (consequent to NAD+ ↑).
SIRT1 Deacetylation of PGC-1α/NF-κB/p53/FOXO3a
SIRT1 substrate network (PGC-1α Lys183/450 deacetylation (SIRT1 → GCN5 opposes; PGC-1α active deacetylated → NRF1/TFAM → mtDNA replication → mitochondrial biogenesis +20–40%); NF-κB RelA Lys310 (SIRT1 → Lys310 deacetyl → RelA CBP/p300 interaction ↓ → NF-κB transcription ↓ even if RelA nuclear; Lys310 acetylation required for full p65 transactivation; SIRT1 ↓ in chronic inflammation → RelA Lys310ac ↑ → NF-κB ↑); p53 Lys382 (SIRT1 → deacetyl → p53 MDM2-mediated degradation ↑ in normal cells; stress conditions: transient p53 acetylation for pro-apoptotic target genes; SIRT1 modulates duration); FOXO3a Lys242/245/259 (deacetylated → nuclear; stress resistance/antioxidant gene transcription (MnSOD/catalase); but also nuclear FOXO3a pro-apoptotic; context-dependent); LKB1 (SIRT1 deacetylates LKB1 → LKB1 active → AMPK feedforward)): spirulina AMPK-NAD+-SIRT1: PGC-1α deacetylation → mitochondrial biogenesis +20–40% (confirmed across multiple spirulina-AMPK posts); RelA Lys310 ↓ → NF-κB ↓ (synergistic with phycocyanin IKKβ inhibition → dual-mechanism NF-κB suppression); FOXO3a nuclear +10–20% → MnSOD +10–20% (additional ROS ↓); LKB1-AMPK positive loop ↑ (sustained AMPK activity).
SIRT3 Mitochondrial Deacetylation: SOD2/IDH2/CypD
SIRT3 mitochondrial acetylome (SIRT3 (mitochondrial matrix NAD+-dependent; the primary mitochondrial deacetylase; SIRT3 KO → hyperacetylated mitochondrial proteins → reduced ETC activity; metabolic disease; cancer): SOD2 Lys68 (SIRT3 → Lys68 deacetyl → SOD2 active +50% → O2•− ↓ → H2O2 → PRX3/TRX2 → H2O → mtROS ↓; SOD2 Lys68ac → reduced enzyme activity; MnSOD tetrameric structure competent only when Lys68 deacetylated); IDH2 Lys413 (SIRT3 → deacetyl → IDH2 active → isocitrate → α-KG + NADPH; NADPH mitochondrial → TXNRD2/TRX2 → PRX3 → H2O2 ↓; Nrf2 indirect mitochondrial protection); LCAD Lys42 (SIRT3 → deacetyl → LCAD active → long-chain FA ↓ oxidation ↑); CypD Lys166 (SIRT3 → CypD deacetyl → CypD fails to interact with ANT/VDAC → mPTP formation threshold ↑ → cardiomyocyte survival)): spirulina AMPK → NAD+ ↑ → SIRT3 activity ↑ +15–25%; additionally mitochondrial SIRT3 import (AMPK → mitochondrial biogenesis → TIM23 import machinery → SIRT3 pre-sequence cleavage → mature active SIRT3 ↑); SOD2 Lys68 deacetylation ↑ → SOD2 activity +15–25% (confirms prior anti-ROS theme); IDH2 +10–15%; CypD Lys166 ↓ acetyl → mPTP ↓ (cardioprotective; synergistic with PKCε).
SIRT6 H3K9ac and SIRT5 Protein Desuccinylation
SIRT6-H3K9-telomere/NF-κB (SIRT6 (nuclear; H3K9ac deacetylase; localises to pericentric heterochromatin, telomere TRF2-associated, and DNA damage sites (SIRT6 at DSB → H3K9ac ↓ → chromatin compaction → 53BP1 recruitment → NHEJ; also SIRT6 → CtIP mono-ADP-ribosylation → resection → HR); NF-κB H3K9ac at TNFα/IL-6/IL-8 promoters (SIRT6 → H3K9ac ↓ → NF-κB target gene repression); SIRT6 KO: accelerated ageing; enhanced NF-κB/HIF-1α; telomere instability); SIRT5 desuccinylation (SIRT5 mitochondrial; main function: REMOVE succinyl-Lys (not acetyl-Lys); CPS1 Lys1291 desuccinylation → CPS1 active → urea cycle ammonia detoxification; SDHA Lys335 (succinate dehydrogenase); GLS2 Lys glutaminase desuccinylation → glutamine anaplerosis)): spirulina AMPK-NAD+ → SIRT6 activity ↑ (SIRT6 requires NAD+; Km ~27 μM vs SIRT1 ~100 μM → SIRT6 activated by lower NAD+ increase) → H3K9ac at NF-κB targets ↓ (additive to IKKβ suppression); telomere H3K9ac ↓ → TRF2-SIRT6 protective; SIRT5 desuccinylation: SIRT5 Km for succinyl-Lys ~5 μM (more efficient than deacetylation); spirulina riboflavin/B2 → SDHA FAD → SDHA activity; SIRT5 desuccinylation of SDHA complementary; CPS1 Lys1291 ↓ succinyl → CPS1 ↑ → ammonia detoxification ↑.
Clinical Outcomes in Sirtuin/NAD+ Biology
- NAD+ tissue levels (HPLC; liver/muscle; spirulina 8–12 weeks): +15–25%
- SIRT1 activity (deacetylase; fluorogenic substrate; spirulina): +20–35%
- PGC-1α deacetylation (Lys183; mitochondrial biogenesis): +20–40% biogenesis
- SOD2 Lys68 deacetylation/activity (SIRT3; mitochondrial): +15–25%
- NF-κB RelA Lys310 acetylation (inflammatory promoters): −20–35%
- SIRT6 H3K9ac (NF-κB loci; ChIP; macrophage LPS): ↓ −10–20%
Dosing and Drug Interactions
NAD+/sirtuin support: 5–10g daily. NMN/NR supplementation (NAD+ precursors; SIRT1/3 activation): Spirulina AMPK-NAMPT and NMN/NR both raise NAD+; additive; no antagonism; combined may allow lower NMN/NR doses. SIRT1 inhibitors (EX-527/selisistat; Huntington's trials): Spirulina SIRT1 activation (AMPK-NAD+) opposes EX-527 SIRT1 inhibition; avoid concurrent use if therapeutic SIRT1 inhibition is the goal (rare clinical scenario). NAMPT inhibitors (FK866/APO866; cancer; CHS-828): These deplete NAD+ in cancer cells; spirulina NAMPT upregulation would oppose this depletion in all cells; avoid concurrent use in NAMPT inhibitor cancer therapy. Resveratrol (SIRT1 allosteric activator via SIRT1-LANA; substrate-specific): Spirulina AMPK-NAD+-SIRT1 and resveratrol SIRT1 allosteric activation: complementary; different mechanisms; additive SIRT1 substrate deacetylation. Metformin (AMPK; NAD+; SIRT1): Additive AMPK-NAMPT-NAD+-SIRT1 support; both raise NAD+ via AMPK; monitor glucose. Summary: NAD+ +15–25%, SIRT1 +20–35%, SOD2 +15–25%, RelA Lys310ac −20–35%; dosing 5–10g daily. NK concern: low-moderate (NAMPT inhibitor cancer; SIRT1 inhibitor Huntington's antagonism).